AAV Triple-Plasmid Design with Stuffer-Based Packaging Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing rAAV production systems face challenges in achieving optimal transfection efficiency and minimizing immunogenicity while maintaining transgene expression, particularly in triple-plasmid systems used for gene therapy.
Innovation Solution
A triple-plasmid system is developed, comprising a transgene-containing plasmid with a stuffer sequence to prevent plasmid backbone packaging, an AAV Rep and Cap gene sequence plasmid, and an adenovirus helper plasmid, where the stuffer sequence is inert and increases the plasmid backbone size to discourage packaging, thereby reducing immunogenicity and enhancing transfection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a triple-plasmid system is used for rAAV production, then transfection efficiency is improved, but immunogenicity increases due to helper virus production
Solution Approach 1:
The patent extracts and removes the adenovirus helper virus from the system by using a plasmid-based helper function delivery mechanism instead of live virus infection. This eliminates the harmful immunogenic effects of helper virus production while maintaining the necessary helper functions for AAV replication and packaging through transient expression of viral proteins from the plasmid.
Solution Approach 2:
The patent introduces an intermediary plasmid vector that carries the adenovirus helper gene sequences but cannot produce infectious virus particles. This intermediary plasmid serves as a mediator to provide helper functions (E1a, E1b, E2a, E4, VA RNA) necessary for AAV replication without the harmful effects of live adenovirus infection, thus reducing immunogenicity while maintaining productivity.
2Reliability
If the plasmid backbone size is increased with a stuffer sequence, then packaging is prevented, but transgene expression may be affected
Solution Approach 1:
The patent applies local quality by adding a stuffer sequence specifically to the plasmid backbone portion that is not required for gene expression. This localized addition increases the plasmid size to prevent packaging of the backbone while leaving the transgene expression cassette intact and functional, thus maintaining transgene expression productivity while achieving reliable packaging control.
Solution Approach 2:
The patent segments the plasmid into distinct functional regions: a minimal backbone containing only essential elements (origin of replication, selectable marker) and a separate transgene expression cassette. The stuffer sequence is added to the backbone segment to increase its size and prevent packaging, while the transgene cassette remains separate and fully functional for expression.
3Productivity
If helper virus infection is used for AAV production, then viral replication is achieved, but residual helper virus causes immune responses
Solution Approach 1:
The patent uses a disposable plasmid-based helper function delivery system that provides viral replication functions temporarily during the production phase. The plasmid expresses helper proteins (E1a, E1b, E2a, E4, VA RNA) only during the transient transfection period, then degrades without integrating into the host genome or producing infectious virus particles, thus avoiding long-term immune responses while achieving necessary viral replication for AAV production.
Data Source
AI summary
A triple-plasmid system for producing recombinant adeno-associated viruses is disclosed.